SEC Form 4 · accession 0000899243-19-002332
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry M. Deutsch
Officer — See Remarks
Period of report
Jan 31, 2019
Accepted (ET)
Feb 1, 2019 · 4:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.88 | Jan 31, 2019 | A | 25,000 | A | — | Jan 31, 2029 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F125% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
Remarks
Chief Financial Officer